Page 126 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Antibody therapeutics in Alzheimer’s

10. Singh Gautam A, Pandey SK, Lasure V, Dubey S, Singh RK. 19. Golde TE. Disease-modifying therapies for Alzheimer’s
Monoclonal antibodies for the management of central disease: More questions than answers. Neurotherapeutics.
nervous system diseases: Clinical success and future 2022;19:209-227.
strategies. Expert Opin Biol Ther. 2023;23(7):603-618.
doi: 10.1007/s13311-022-01201-2
doi: 10.1080/14712598.2023.2098875
20. Brunello CA, Merezhko M, Uronen RL, Huttunen HJ.
11. Das B, Yan R. A close look at BACE1 inhibitors for Alzheimer’s Mechanisms of secretion and spreading of pathological tau
disease treatment. CNS Drugs. 2019;33(3):251-263. protein. Cell Mol Life Sci. 2020;77(9):1721-1744.
doi: 10.1007/s40263-019-00623-4 doi: 10.1007/s00018-019-03349-1
12. Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic 21. Panza F, Lozupone M. The challenges of anti-tau therapeutics
antibodies for the treatment of diseases. J Biomed Sci. in Alzheimer’s disease. Nat Rev Neurol. 2022;18:577-578.
2020;27:1.
doi: 10.1038/s41582-022-00702-0
doi: 10.1186/s12929-019-0602-2
22. Plotkin SS, Cashman NR. Passive immunotherapies
13. Pothin E, Lesuisse D, Lafaye P. Brain delivery of single-
domain antibodies: A focus on VHH and VNAR. targeting Aβ and tau in Alzheimer’s disease. Neurobiol Dis.
Pharmaceutics. 2020;12:937. 2020;144:105010.
doi: 10.3390/pharmaceutics12100937 doi: 10.1016/j.nbd.2020.105010
14. Marino M, Zhou L, Rincon MY, et al. AAV-mediated 23. Parrocha CMT, Nowick JS. Current peptide vaccine and
delivery of an anti-BACE1 VHH alleviates pathology in an immunotherapy approaches against Alzheimer’s disease.
Alzheimer’s disease model. EMBO Mol Med. 2022;14:e09824. Pept Sci (Hoboken). 2023;115:e24289.
doi: 10.15252/emmm.202009824 doi: 10.1002/pep2.24289
15. Yadav DB, Maloney JA, Wildsmith KR, et al. Widespread 24. Galpern WR, Mercken M, Van Kolen K, et al. A single
brain distribution and activity following i.c.v. infusion of ascending dose study to evaluate the safety, tolerability,
anti-β-secretase (BACE1) in nonhuman primates. Br J pharmacokinetics, and pharmacodynamics of the anti-
Pharmacol. 2017;174(23):4173-4185. phospho-tau antibody JNJ-63733657 in healthy subjects.
Alzheimers Dement. 2019;15(7S_Part_5):P252-P253.
doi: 10.1111/bph.14055
doi: 10.1016/j.jalz.2019.06.077
16. Burns S, Selman A, Sehar U, Rawat P, Reddy AP, Reddy PH.
Therapeutics of Alzheimer’s disease: Recent developments. 25. Guo X, Yan L, Zhang D, Zhao Y. Passive immunotherapy for
Antioxidants (Basel). 2022;11(12):2402. Alzheimer’s disease. Ageing Res Rev. 2024;94:102192.
doi: 10.3390/antiox11122402 doi: 10.1016/j.arr.2024.102192
17. Rawat P, Sehar U, Bisht J, Selman A, Culberson J, 26. Jurcau A, Nunkoo VS. Tau-targeted therapy in Alzheimer’s
Hemachandra Reddy P. Phosphorylated Tau in Alzheimer’s disease-history and current state. Front Clin Drug Res
disease and other tauopathies. Int J Mol Sci. 2022;23:12841. Dementia. 2021;2:56.
doi: 10.3390/ijms232112841 27. Novak P, Zilka N, Zilkova M, et al. AADvac1, an active
18. Sexton C, Snyder H, Beher D, et al. Current directions in immunotherapy for Alzheimer’s disease and non-Alzheimer
tau research: Highlights from Tau 2020. Alzheimers Dement. tauopathies: An overview of preclinical and clinical
2022;18:988-1007. development. J Prev Alzheimers Dis. 2019;6:63-69.
doi: 10.1002/alz.12452 doi: 10.14283/jpad.2018.45

Volume 7 Issue 3 (2024) 6 doi: 10.36922/itps.2953